November TANOVEA®-CA1 Webinar Vlog – Anticipating and Addressing Adverse Effects

Posted on November 22nd, 2017 by Tom Schek

As part of a TANOVEA CA-1 Tuesdays webinar, Douglas H. Thamm, VMD, DACVIM (Oncology), presents information for veterinarians on possible adverse effects of treatment with the canine lymphoma drug, and explores strategies for anticipating and mitigating common gastrointestinal effects. This … Keep Reading

Cancer Treatment for Dogs and How Dogs Improve Our Health

Posted on November 9th, 2017 by Tom Schek

When your canine companion receives a lymphoma diagnosis, you naturally seek the latest cancer treatment for dogs (such as TANOVEA®-CA1 (rabacfosadine for injection)). But its not just owners who take care of dogs, dogs also take care of us. Studies have shown … Keep Reading

VetDC Announces New TANOVEA®-CA1 Publication, State of the Art Presentation at VCS 2017 Annual Conference

Posted on November 3rd, 2017 by Tom Schek

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology. Data from this publication and several new VetDC-sponsored studies was prominently featured in a State … Keep Reading

TANOVEA-CA1 Noted in Veterinary Brief Article

Posted on October 25th, 2017 by Tom Schek

As Sue Ettinger, DVM, DACVIM (Oncology), of Tarrytown, New York, explains in a new article on the Veterinary Brief website, canine lymphoma, one of the most common canine cancers, is actually a collection of cancers arising from the malignant transformation … Keep Reading

VetDC/CSU Partnership Highlighted in Article on Research Spending

Posted on October 11th, 2017 by Tom Schek

TANOVEA®-CA1 (rabacfosadine for injection), a novel treatment for lymphoma in dogs, is the result of a powerful collaboration involving VetDC, veterinarians nationwide, and the families that allow us to care for their dogs with lymphoma. VetDC was originally founded out … Keep Reading

New Study for Treatment of Relapsed B-cell Lymphoma in Dogs

Posted on September 28th, 2017 by Tom Schek

TANOVEA®-CA1 (rabacfosadine for injection) is a novel double prodrug that targets cancerous lymphoma cells and is the first FDA conditionally approved drug for the treatment of lymphoma in dogs. Previous studies have suggested that administration of rabacfosadine every 3 weeks can achieve … Keep Reading

Second Chance: Knoxville Vet Clinic Offers New Canine Cancer Treatment

Posted on September 20th, 2017 by Tom Schek

Friday September 15, 2017 KNOXVILLE, TN (Knoxville News Sentinel, by Jim Gaines) — When Lyla, a 6-year-old boxer, developed lumps in her throat and one on each hind leg, her owners Robin and Karen Hedden were afraid they knew what was wrong.When … Keep Reading

Canine Lymphoma Patient Receives Final TANOVEA-CA1 treatment

Posted on September 14th, 2017 by Tom Schek

Canine lymphoma patient Nettie receives her final treatment with TANOVEA-CA1 (Rabacfosadine for injection) TANOVEA-CA1, the first lymphoma treatment for dogs conditionally approved by the FDA, is administered in five in-office visits by a team consisting of a veterinarian and trained … Keep Reading

Canine Lymphoma: 9 Indicators to Look For

Posted on August 23rd, 2017 by Tom Schek

Nobody wants to think about their dog getting lymphoma, but unfortunately it is one of the most common cancers in dogs today. Thus it is important to be aware of common indicators that can help you determine when to consult … Keep Reading

My Dog has Lymphoma: What Do I Do Now?

Posted on August 9th, 2017 by Tom Schek

My dog has lymphoma. It’s a sentence you never want to hear yourself speaking. Unfortunately, lymphoma is one of the most common cancers in dogs. Many owners will be faced with learning how to deal with that diagnosis and the … Keep Reading